Cassava Sciencesの空売り状況は、投資家がCassava Sciencesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Cassava Sciences (NASDAQ:SAVA) 株価情報, 空売り情報

Cassava Sciences

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.

Cassava Sciences Inc

Cassava Sciences Inc Warrants (15/11/2024)

SAVANNAH GOLDFIELDS LTD by SAVANNAH GOLDFIELDS LTD

Savannah Energy PLC

SAVANNAH RESOURCES PLC by SAVANNAH RESOURCES PLC

Savannah Resources PLC

Savara Inc

Savaria Corp

Earnings

Earnings Beats

News

Booz Allen Hamilton Q3 2025 Adj. EPS $1.55 Beats $1.51 Estimate, Sales $2.917B Beat $2.864B Estimate

Merck Says Committee For Medicinal Products For Human Use Of The European Medicines Agency Recommended The Approval Of CAPVAXIVE For Active Immunization Of Invasive Disease And Pneumonia Caused By Streptococcus Pneumoniae

TDK (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TTDKY#OTC">TTDKY</a>) reported its Q3 earnings results on Friday, January 31, 2025 at 03:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
TDK beat estimated earnings by 6.0%, reporting an EPS of $0.19 versus an estimate of $0.18.
Revenue was up $29.00 million from the same period last year.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat on EPS by $0.17 which was followed by a 4.0% increase in the share price the next day.
Here's a look at TDK's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.20</td>
<td>0.10</td>
<td>0.04</td>
<td>0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.37</td>
<td>0.22</td>
<td>0.02</td>
<td>0.23</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.98B</td>
<td>3.19B</td>
<td>3.23B</td>
<td>3.84B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.83B</td>
<td>3.33B</td>
<td>3.27B</td>
<td>3.79B</td>
</tr>
</tbody>
</table>

To track all earnings releases for TDK <a href="https://www.benzinga.com/quote/TTDKY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TTDKY

TDK Q3 Earnings Assessment

Evercore ISI Group analyst James Kammert initiates coverage on NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) with a In-Line rating and announces Price Target of $42.

Price Target

Initiation

Analyst Ratings

Evercore ISI Group Initiates Coverage On NNN REIT with In-Line Rating, Announces Price Target of $42

Fujitsu (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FJTSY#OTC">FJTSY</a>) lowers FY2024 GAAP EPS guidance from $0.77 to $0.76. Lowers FY2024 sales outlook from $25.26 billion to $22.78 billion.

Guidance

FJTSY

Fujitsu Lowers FY2024 GAAP EPS Guidance from $0.77 to $0.76; Lowers FY2024 Sales Guidance from $25.26B to $22.78B

WIIM

Signing Day Sports shares are trading higher after the company announced it retains rights as the National Recruiting Partner to the U.S. Army Bowl through 2026 in new deal.

Fujitsu (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FJTSY#OTC">FJTSY</a>) lowers FY2024 Adj EPS guidance from $0.82 to $0.81. sees Adj sales of $22.784 billion.

Fujitsu Lowers FY2024 Adj EPS Guidance from $0.82 to $0.81; Sees Adj Sales $22.784B

B of A Securities analyst Jessica Reif Cohen downgrades Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) from Buy to Neutral and lowers the price target from $50 to $38.

Downgrades

CMCSA

B of A Securities Downgrades Comcast to Neutral, Lowers Price Target to $38

Signing Day Sports Announced The Signing Of A New Sponsorship Agreement With The US Army Bowl  Through 2026, Extending Its Rights As "National Recruiting Partner"

Fujitsu (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FJTSY#OTC">FJTSY</a>) reported quarterly earnings of $0.04 per share. This is a 200 percent increase over losses of $(0.04) per share from the same period last year. The company reported $6.07 billion in sales this quarter. This is a 3.63 percent decrease over sales of $6.30 billion the same period last year.

Fujitsu Q3 EPS $0.04 Up From $(0.04) YoY, Sales $6.07B Down From $6.30B YoY

U.S. stock futures climbed on Friday, pointing to a third straight week of gains fueled by strong corporate earnings. Futures were higher for all four major indices.
The dollar index strengthened after Donald Trump announced Thursday that the U.S. will implement a 25% tariff on imports from Canada and Mexico, effective Saturday, Feb. 1. He also threatened the <a href="https://www.benzinga.com/government/regulations/25/01/43377987/after-imposing-tariffs-on-canada-donald-trump-threatens-100-levy-on-brics-for-move-against-dollar-how-will-us-manage-production-from-slippers-to-ships-asks-expert">BRICS nations</a> to impose 100% tariffs if they issue BRICS reserve currency.
Investors await the Personal Consumption Expenditure data for December, which will be released before the market opens.
The 10-year Treasury yield is currently at 4.53%, and the two-year yield is at 4.21%. The CME Group&#8217;s FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.htm">tool </a>indicates an 82% probability that the Federal Open Market Committee will maintain current interest rates in March 2025.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.78%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.45%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.34%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.01%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday, both the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) were higher. SPY was up 0.42% at $607.59, and QQQ gained 0.80% to reach $527.22, based on <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Stocks rallied Thursday following mixed reactions to a wave of earnings reports and economic data.
This followed Wednesday&#8217;s down session after the Fed held rates steady. Investor sentiment fluctuated due to DeepSeek&#8217;s low-cost AI model launch and Big Tech earnings, this week.
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares fell 0.74% despite beating first-quarter revenue and earnings estimates as iPhone sales slipped in 2024 to $69.14 billion, versus $69.7 billion last year. Revenue reached $124.3 billion as compared to $124.13 billion expected by Benzinga Pro, and adjusted earnings per share was $2.40 as compared to the expectation of $2.36 per share.
IBM Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) surged nearly 13% on artificial intelligence growth, Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) gained 1.6% on strong results, while Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) fell 6.2% despite exceeding expectations due to weaker cloud revenue.
On the economic front, Q4 GDP growth and jobless claims were slightly below forecasts, but overall economic indicators remain strong, with the Fed, on Wednesday, citing a robust labor market and &#8220;somewhat elevated&#8221; inflation.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.25%</td>
<td>19,681.75</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.53%</td>
<td>6,071.17</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.38%</td>
<td>44,882.13</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.07%</td>
<td>2,307.45</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
According to the analysts at BlackRock, strong corporate earnings have set the tone for the fourth-quarter season in swing.
&#8220;Even with higher-for-longer interest rates, we think U.S. stocks can keep outperforming this year. We stay overweight. Resilient economic growth is helping sectors beyond tech. That's partly driven by artificial intelligence (AI) spurring earnings beyond the initial winners during an economic transformation and policy change, we think. Yet we eye risks to risk appetite changing this year depending on earnings and policy.&#8221;
With interest rates in focus Ed Yardeni and Eric Wallerstein of Yradeni Research, said in their QuickTakes note that Fed Chair Jerome Powell&#8217;s basic message during his press conference was that the Fed is in no hurry to lower interest rates, but the Fed still intends to lower them over time.
Hence, they described it as a &#8220;dovish pause&#8221;.
Approaching the week from a technical perspective Jeff Buchbinder, the chief equity strategist at LPL Financial said that the S&amp;P 500 remains near record-high territory amid improving market breadth and momentum. &#8220;Technical damage within the heavy-weight tech sector has been minimal as buyers stepped up near support from the mid-January lows.&#8221;
Despite Monday's pullback, sector breadth is also holding up relatively well, with the majority of tech stocks trading above their 200-day moving average, Buchbinder added.
&#8220;However, technical damage has been more pronounced on a relative basis, as the tech sector vs. S&amp;P 500 ratio chart recently dropped to multi-month lows,&#8221; he said.
See Also:&nbsp;<a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Friday:
<ul>
<li>Fed Governor Michelle Bowman will be speaking at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Employment cost index data for Q4 will be released at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Also, the core and headline personal consumption expenditure, along with personal income and spending data will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>The Chicago Business Barometer (PMI) for January will be out by 9:45 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) was up 3.46% in the premarket on Friday after beating the fourth-quarter expectations on Tuesday, despite a slip in iPhone sales.</li>
</ul>
<ul>
<li>Colgate-Palmolive Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) was up 0.03% as Wall Street expects it to report earnings of 89 cents per share on revenue of $4.99 billion, before the opening bell.</li>
</ul>
<ul>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) fell 0.86% ahead of its earnings to be released before the opening bell. Analysts expect it to report quarterly earnings of 23 cents per share on revenue of $32.24 billion.</li>
</ul>
<ul>
<li>Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) was down 0.17% as Wall Street expects it to report earnings of $2.11 per share on revenue of $48.41 billion, before the opening bell.</li>
</ul>
<ul>
<li>Other companies that are slated to report earnings today included Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) up 0.6%, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) up 1.49%, Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) up 2.09%, AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) up 0.99%, WW Grainger Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) up 1.05% and Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) up 2.09%.</li>
</ul>
<ul>
<li>Nauticus Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) was up 46.15% after announcing a partnership to advance subsea autonomy solutions.</li>
</ul>
<ul>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) was up 19.57% after the company announced a $50 million investment from Softbank.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.08% to hover around $72.67 per barrel.
The gold spot index was down by 0.08% to $2,791.94 per ounce. The Dollar Index was up 0.42% at 108.246 level.
Asian markets were higher on Friday except South Korea's Kospi index. Australia's ASX 200, Japan's Nikkei 225, South Korea's Kospi, Hong Kong's Hang Seng, and India's S&amp;P BSE Sensex rose. European markets were also higher in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43376448/elon-musks-x-money-to-see-about-600-million-active-monthly-users-via-visa-direct-integration">Elon Musk&#8217;s &#8216;X Money&#8217; To See About 600 Million Active Monthly Users Via Visa Direct Integration: &#8216;Excited To Partner,&#8217; Says CEO</a></li>
</ul>
Photo courtesy: Shutterstock

Analyst Color

Equities

Government

Market Summary

Regulations

Bonds

Broad U.S. Equity ETFs

Futures

Forex

Treasuries

Pre-Market Outlook

Markets

ETFs

General

AAPL

ABBV

CHTR

CIFR

KITT

MSFT

US Stock Futures Climb After Apple Beats Q4 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact

OneMain Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMF#NYSE">OMF</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.15 by 0.87 percent. This is a 16.55 percent decrease over earnings of $1.39 per share from the same period last year. The company reported quarterly sales of $1.01 billion which missed the analyst consensus estimate of $1.04 billion by 3.27 percent. This is a 10.03 percent increase over sales of $917.00 million the same period last year.

Earnings Misses

OneMain Holdings Q4 Adj EPS $1.16 Beats $1.15 Estimate, Sales $1.01B Miss $1.04B Estimate

Autoliv Sees FY25 Organic Growth Of About 2%

In November 2024, a positive opinion was received from the Committee for Medicinal Products for Human Use (CHMP) recommending approval of lecanemab.1 As part of its decision-making process, the European Commission (EC) has asked the CHMP to consider information on the safety of lecanemab that became available after the adoption of the CHMP opinion in November 2024 and whether this may require an update of the opinion, and to consider whether the wording of the risk minimization measures in the opinion is clear enough to ensure correct implementation. These will be discussed at the CHMP meeting in February 2025.
 &nbsp;

BIIB

Biogen And Eisai Reveals Update On Ongoing Regulatory Review Of Marketing Authorization Application For lecanemab As Treatment For Early AD In European Union

For the full year 2025, the company is issuing the following guidance:
<ul>
<li>Organic growth of 7-9%</li>
<li>Segment margins of 24.4-24.8%</li>
<li>Earnings per share between $10.60 and $11.00, up 14% at the midpoint over the prior year</li>
<li>Adjusted earnings per share between $11.80 and $12.20, up 11% at the midpoint over the prior year</li>
</ul>
For the first quarter of 2025, the company anticipates:
<ul>
<li>Organic growth of 5.5-7.5%</li>
<li>Segment margins of 23.7-24.1%</li>
<li>Earnings per share between $2.30 and $2.40</li>
<li>Adjusted earnings per share between $2.65 and $2.75</li>
</ul>

Eaton For 2025 Expects 7-9% Organic Growth, And Adjusted EPS Between $11.80 And $12.20 Vs. $10.71 Est.; For Q1 Expects 5.5-7.5% Organic Growth, And Adjusted EPS Of $2.65-$2.75 Vs. $2.81 Est.

TDK (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TTDKY#OTC">TTDKY</a>) announced its Q3 earnings on Friday, January 31, 2025 at 03:00 AM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
TDK beat estimated earnings by 6.0%, reporting an EPS of $0.19 versus an estimate of $0.18.
Revenue was up $29.00 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.17 in the last quarter, resulting in a 4.0% increase share price change the following day.
Here's a look at TDK's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.20</td>
<td>0.10</td>
<td>0.04</td>
<td>0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.37</td>
<td>0.22</td>
<td>0.02</td>
<td>0.23</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.98B</td>
<td>3.19B</td>
<td>3.23B</td>
<td>3.84B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.83B</td>
<td>3.33B</td>
<td>3.27B</td>
<td>3.79B</td>
</tr>
</tbody>
</table>

To track all earnings releases for TDK <a href="https://www.benzinga.com/quote/TTDKY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TDK Earnings Report: Q3 Overview

Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) reported quarterly adjusted earnings of $3.05 per share which beat the analyst consensus estimate of $2.83 by 7.77 percent. This is a 18.45 percent decrease over earnings of $3.74 per share from the same period last year. The company reported quarterly sales of $2.62 billion which missed the analyst consensus estimate of $2.70 billion by 3.26 percent. This is a 4.91 percent decrease over sales of $2.75 billion the same period last year.

Autoliv Q4 Adj $3.05 Beats $2.83 Estimate, Sales $2.62B Miss $2.70B Estimate

LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) reported quarterly earnings of $0.75 per share which met the analyst consensus estimate. This is a 40.48 percent decrease over earnings of $1.26 per share from the same period last year. The company reported quarterly sales of $9.497 billion which beat the analyst consensus estimate of $9.225 billion by 2.95 percent. This is a 4.35 percent decrease over sales of $9.929 billion the same period last year.

LyondellBasell Industries Q4 2024 Adj. EPS $0.75, Inline, Sales $9.497B Beat $9.225B Estimate

Needham analyst Quinn Bolton reiterates Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) with a Buy and maintains $20 price target.

Reiteration

MBLY

Needham Reiterates Buy on Mobileye Global, Maintains $20 Price Target

Citigroup analyst Leandro Bastos downgrades Afya (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFYA#NASDAQ">AFYA</a>) from Neutral to Sell and lowers the price target from $18 to $15.

AFYA

Citigroup Downgrades Afya to Sell, Lowers Price Target to $15

Stocks are a mixed bag this afternoon, with the S&P 500 Index and Nasdaq Composite earlier touching fresh record highs as the latter jumps triple digits.

S&P 500, Nasdaq Hit Record Highs To Start December

THE LAWSUIT: A class action securities lawsuit was filed against Cassava Sciences, Inc. (SAVA) that seeks to recover losses of Cassava Sciences, In...

Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky LLP

Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market.

Top Biotech Short Squeeze Stocks

Catalyst Watch: Labor pains for Amazon & Starbucks, Nasdaq call-up for MicroStrategy and Pony AI ratings

Investors Looking To Durable Goods, New-Home Sales Data As Earnings Season Winds Down

Most shorted stocks on Wall Street heading into 2025: BYND, KSS, GRPN, and more

Notable profits for the buyer who lifted the $0.25 offer for 9,851 Cassava Sciences (SAVA) Feb-25 3 calls yesterday at 10:51ET when underlying shar...

Cassava Sciences call buyer realizes 60% same-day gains

Cassava Science provided a business update. In November 2024, Cassava reported that the topline results from the Phase 3 RETHINK-ALZ study evaluati...

Cassava Sciences to reduce workforce by 33%

Cassava laying off one-third of staff to curb expenses

Simufilam's Collapse Leaves Cassava Searching For A Viable Future

ALMS

AMTM

AMZN

AVGO

AXON

BYND

CRVL

CRVO

CVLG

DXST

EVGO

GALT

GLATF

GOEV

GRPN

ILMN

KELYA

LAZR

LMNR

MRNA

MSTR

MTEM

NDSN

NMRA

NUKK

PHAT

PLTR

PONY

QMCO

QRVO

QUBT

RYTM

SAVA

SBUX

SLNO

SMCI

SPHR

WBTN

WDAY

WOLF

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA

SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA

Legal

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kaspi, Sun Communities, Cassava, and MGPI and Encourages Investors to Contact the Firm

The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 – SAVA

Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact The Gross Law Firm

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc.(SAVA) Shareholders

SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Comments

Cassava Sciences

空売り

Cassava Sciences (NASDAQ:SAVA) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル